Medicus Pharma licenses Pfizer CD228V antibody-drug conjugate in deal worth more than $1bn
Medicus Pharma has secured exclusive worldwide rights to Pfizer's CD228-targeted antibody-drug conjugate PF-08046031 in an oncology licensing agreement potentially worth more than $1 billion.
Medicus will pay Pfizer $12 million upfront and a further $15 million after one year, with Pfizer eligible for more than $1 billion in development, regulatory and commercial milestone payments plus royalties on future sales.
The transaction adds a potentially first-in-class CD228-targeted antibody-drug conjugate to Medicus' oncology pipeline and gives the company responsibility for its future development and commercialisation worldwide.
Field | Content |
Alert Type | Deal |
Companies | Medicus Pharma; Pfizer |
Deal Type | Exclusive worldwide licensing agreement |
Asset or Company | PF-08046031 / CD228V |
Therapy Area(s) | Oncology; solid tumours |
Technology or Modality | CD228-targeted antibody-drug conjugate |
Deal Value | US$12 million upfront, US$15 million after one year, more than US$1 billion in potential development, regulatory and commercial milestones, plus royalties |
Geography | Worldwide |
What Happened | Medicus Pharma secured exclusive worldwide rights from Pfizer to develop and commercialise the CD228-targeted antibody-drug conjugate PF-08046031, also known as CD228V. |
Why It Matters | The agreement gives Medicus control of a potentially differentiated oncology asset targeting CD228 and represents a substantial expansion of the company's therapeutic pipeline. |
Supporting Context | PF-08046031 is an early-stage antibody-drug conjugate designed to target CD228, a cell-surface protein expressed across several tumour types. |
Strategic Rationale | Medicus gains a global oncology development asset while Pfizer retains substantial economic participation through milestone payments and royalties. |
Potential Impact | Successful development could establish a new targeted treatment approach for cancers expressing CD228 and materially broaden Medicus' oncology portfolio. |
Key Takeaway | Medicus Pharma has licensed Pfizer's CD228V antibody-drug conjugate globally in a transaction carrying more than US$1 billion in potential milestone payments. |
What to Watch | Medicus' development plans for PF-08046031, progression into further clinical evaluation and selection of priority tumour indications. |
Primary Source | U.S. Securities and Exchange Commission |
Relevant Date | 11 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare